Generex Announces Featured Presentation of Cancer Immunotherapy Developed by Subsidiary at OPT Boston

Generex Biotechnology Corporation GNBTD today announced that Dr. Eric von Hofe, Ph.D., President of the Company's wholly-owned immuno-therapeutics subsidiary, Antigen Express, Inc. (www.antigenexpress.com), will be a featured speaker at the Cambridge Healthtech Institute's second annual Oligonucleotide & Peptide Therapeutics conference (OPT Boston) (www.optcongress.com) being held in Cambridge, MA March 27 – 29, 2017.

OPT Boston has been established to convene leading developers and technology providers to discuss advances in the discovery, development and delivery of next-generation oligonucleotide and peptide therapies. This three-day event includes two main conferences covering topics within discovery, clinical development, delivery, formulation and manufacturing, as well as two symposia focused on applications within oncology and immunotherapy. Dr. von Hofe's Featured Presentation, Advantages of a Peptide-Based Vaccine Designed to Activate CD4+ T Cells in Cancer Immunotherapy, is scheduled for 8:30 am EDT on Wednesday, March 29 as part of the Peptides in Cancer Therapy symposium.

Antigen Express, an immuno-oncology company focused on the development and commercialization of immunotherapies based on the Ii-Key antigen delivery technology, has conducted extensive clinical studies of its novel cancer vaccines. Clinical studies have demonstrated long-lasting activation of immune cells as well as encouraging efficacy signals in a controlled, randomized Phase II study of its lead compound in newly diagnosed breast cancer patients.

Dr. von Hofe stated: "The low toxicity and high specificity of Antigen Express peptides make them particularly attractive for combination studies with checkpoint inhibitors. While these latter agents have revolutionized the treatment of a variety of cancers in the last few years, efficacy is limited to roughly 30% of treated patients." There is good consensus in the scientific community that the reason for lack of efficacy in the remaining patients is due in part to an insufficient number of specifically activated immune cells.

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170327005241/en/